Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Extendicare has the GF Score of 74, which implies that the company
is
Likely to have average performance.
The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.
GF Score takes following five key aspects into consideration:
Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.
Based on research and backtesting result, GuruFocus believes Extendicare
is
Likely to have average performance.
Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.
Extendicare (LTS:0S9E) GF Score Explanation
Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:
GF Score
Performance Potential and All-in-One Screener Examples (1)
(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.
Extendicare GF Score Related Terms
LTS:0S9E vs HCA, THC, DVA: GF Score Comparison
For the Medical Care Facilities subindustry, Extendicare's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Extendicare GF Score vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Extendicare's GF Score distribution charts can be found below:
* The bar in red indicates where Extendicare's GF Score falls into.
Extendicare (LTS:0S9E) has a GF Score of 74 as of Jul. 26, 2026. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Extendicare and its competitors. This is 10% below median its historical median of 82.00. Over the past decade, Extendicare's GF Score has ranged from 23.00 to 93.00.
Is Extendicare's GF Score too high?
Extendicare's current GF Score of 74 is 10% below median its 10-year median of 82.00. Over the past 10 years, this metric has ranged from a low of 23.00 to a high of 93.00. Overall, Extendicare has a GF Score™ of 74/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Extendicare's GF Score compare to HCA and THC?
Extendicare's GF Score of 74 can be compared against companies in the Healthcare Providers & Services industry. Historically, Extendicare's own GF Score has ranged from 23.00 to 93.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Score for a Healthcare Providers & Services company?
A good GF Score depends on the Healthcare Providers & Services industry context. However, GF Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Score mean?
A high GF Score can signal that a stock is expensive relative to its fundamentals. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Extendicare and its competitors. Extendicare's current GF Score is 74, which is 10% below median its own 10-year median of 82.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Extendicare stock overvalued right now?
Based on GuruFocus' analysis, Extendicare (LTS:0S9E) is currently considered Significantly Overvalued. The stock's GF Value™ is C$14.27, compared to a current price of C$37.76 — trading 164.6% above its estimated fair value. The current GF Score is 74, which is 10% below median its 10-year median of 82.00. Extendicare's overall GF Score™ is 74/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Score calculated?
GF Score is calculated from a company's financial statements. For Extendicare (LTS:0S9E), the current GF Score is 74 as of Jul. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Extendicare (LTS:0S9E) Overvalued in 2026?
Based on GuruFocus' analysis, Extendicare stock appears to be overvalued.
The current stock price of C$37.76 is trading 164.6% above its estimated GF Value™ of C$14.27.
GuruFocus considers Extendicare to be Significantly Overvalued.
Key valuation signals for LTS:0S9E:
GF Score: 74 (10% below median its 10-year median of 82.00)
GF Value™: C$14.27 vs. price of C$37.76 (164.6% above fair value)
No single metric tells the full story. See the LTS:0S9E stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Extendicare Inc is a senior care provider in Canada, focused on long-term care and home health care. The has three main business segments: Long-term Care (LTC), Home Health Care, and Managed Services. The Long-term Care segment, operating under the Extendicare brand, represents 53 owned homes in Ontario, Alberta and Manitoba. The Home Health Care segment, operating under the ParaMed brand, provides home health care services annually in Ontario, Alberta, Manitoba and Nova Scotia. The Managed Services segment, operating under the Extendicare Assist and SGP Purchasing Partner Network brands, provides management, consulting and group purchasing services to other care providers across Canada. The majority of the company's revenue is derived from the Long-term Care segment.
74GF Score
Get the complete analysis for LTS:0S9E
GF Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0S9E has been successfully added to your 
